Objective： We observe the curative effect, median survival time, time to progression, quality of life and adverse effect of patients with advanced refractory non-small cell lung cancer （NSCLC） after gefitinib （Ire...Objective： We observe the curative effect, median survival time, time to progression, quality of life and adverse effect of patients with advanced refractory non-small cell lung cancer （NSCLC） after gefitinib （Iressa） treatment. Methods： Forty-one patients with grade Ⅲb to Ⅳ NSCLC previously treated with two chemotherapy including 85.4% of patients after second line therapy were chosen. The regimen was oral intake of gefitinib 250 mg once daily until the disease progression or toxic reaction has become intolerable. The patients were required to receive tumor evaluation before the treatment, one month, two month and every three months after Iressa administration. Results： All of 41 patients were evaluable for therapeutic effect. Without complete regression being observed, partial response rate （PR）, stable disease （SD） and progression of disease （PD） were 43.9% （18/41）, 34.1% （14/41） and 22.1% （9/41）, respectively. The overall response rate was 43.9% （18141） and disease control rate （PR ＋ SD） was 78% （32/41）. The response rate in male was 42.1%, while it in female was 45.5% （P 〉 0.05）. Twenty-two of them （53.7%, 22/41） were still alive with 10.1 months of MST when the follow-up ended in November 2006. TTP and MST of patients who died was 2.7 and 5.0 months, respectively. The rate of symptom improvement was 78% of all patients with 13 months of MST of PR patients. The Karnofsky enhanced 20 ＋ 5 after 28 days treatment without 3-4 degree of reactive toxicity. Conclusion： Iressa has significant antitumor activity in advanced NSCLC patients who have previously failed in second or third line chemotherapy. Iressa is effective and safe for patients with poor performance status.展开更多
肺癌是肺部常见的恶性肿瘤。1985年以来肺癌已成为全世界最常见的恶性肿瘤。2008年中国肺癌新发病例数约52.2万，占所有恶性肿瘤发病例数的18.5%；死亡例数约45.3万，占所有恶性肿瘤死亡例数的23.1%。其中约80%是非小细胞肺癌（NSCLC）...肺癌是肺部常见的恶性肿瘤。1985年以来肺癌已成为全世界最常见的恶性肿瘤。2008年中国肺癌新发病例数约52.2万，占所有恶性肿瘤发病例数的18.5%；死亡例数约45.3万，占所有恶性肿瘤死亡例数的23.1%。其中约80%是非小细胞肺癌（NSCLC），约有40%～50%的患者在确诊时已经是 IV 期，存在远处淋巴转移或血行转移［1］，脑转移患者发病率也呈上升趋势。我科2010年1月至2012年12月收治晚期非小细胞肺癌患者215例，其中临床诊断为脑转移患者24例，现将其临床中药治疗及生存情况分析如下。展开更多
文摘Objective： We observe the curative effect, median survival time, time to progression, quality of life and adverse effect of patients with advanced refractory non-small cell lung cancer （NSCLC） after gefitinib （Iressa） treatment. Methods： Forty-one patients with grade Ⅲb to Ⅳ NSCLC previously treated with two chemotherapy including 85.4% of patients after second line therapy were chosen. The regimen was oral intake of gefitinib 250 mg once daily until the disease progression or toxic reaction has become intolerable. The patients were required to receive tumor evaluation before the treatment, one month, two month and every three months after Iressa administration. Results： All of 41 patients were evaluable for therapeutic effect. Without complete regression being observed, partial response rate （PR）, stable disease （SD） and progression of disease （PD） were 43.9% （18/41）, 34.1% （14/41） and 22.1% （9/41）, respectively. The overall response rate was 43.9% （18141） and disease control rate （PR ＋ SD） was 78% （32/41）. The response rate in male was 42.1%, while it in female was 45.5% （P 〉 0.05）. Twenty-two of them （53.7%, 22/41） were still alive with 10.1 months of MST when the follow-up ended in November 2006. TTP and MST of patients who died was 2.7 and 5.0 months, respectively. The rate of symptom improvement was 78% of all patients with 13 months of MST of PR patients. The Karnofsky enhanced 20 ＋ 5 after 28 days treatment without 3-4 degree of reactive toxicity. Conclusion： Iressa has significant antitumor activity in advanced NSCLC patients who have previously failed in second or third line chemotherapy. Iressa is effective and safe for patients with poor performance status.
文摘肺癌是肺部常见的恶性肿瘤。1985年以来肺癌已成为全世界最常见的恶性肿瘤。2008年中国肺癌新发病例数约52.2万，占所有恶性肿瘤发病例数的18.5%；死亡例数约45.3万，占所有恶性肿瘤死亡例数的23.1%。其中约80%是非小细胞肺癌（NSCLC），约有40%～50%的患者在确诊时已经是 IV 期，存在远处淋巴转移或血行转移［1］，脑转移患者发病率也呈上升趋势。我科2010年1月至2012年12月收治晚期非小细胞肺癌患者215例，其中临床诊断为脑转移患者24例，现将其临床中药治疗及生存情况分析如下。
